Latest Breaking News On - Celcuity inc view - Page 1 : comparemela.com

Celcuity Inc : Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress

Median progression free survival (PFS) was 48.6 months in treatment-naïve patients with HR+/HER2- advanced breast cancer who were treated with gedatolisib in combination with palbociclib and letrozoleMedian

San antonioUnited statesVicky hahneRobert uhlBrian sullivanIgor gorbatchevskyBreast cancer congress see tableBreast cancer annual congressEuropean society for medical oncologyExchange commission onCelcuity inc viewCelcuity incMedical oncologyEscalation armExpansion armSan antonio breast cancer symposium

Celcuity Inc Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call

Celcuity Inc Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Robert uhlBrian sullivanVicky hahneCelcuity inc viewCelcuity incConference callGefallene big techs

Celcuity Inc : Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023

Gedatolisib demonstrated superior anti-proliferative potency and efficacy in endometrial, ovarian and cervical cancer cell lines compared to other PAM inhibitors evaluated regardless of PTEN, P13K, or

United statesVicky hahneCelcuity celsigniaRobert uhlBrian sullivanCelcuity inc viewCelcuity incExchange commission onAmerican associationCancer researchChief executive officerRisk factorsAnnual reportExchange commission

Celcuity Inc : Celcuity to Participate in 22nd Annual Needham Virtual Healthcare Conference

MINNEAPOLIS, MN / ACCESSWIRE / April 12, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced its participation

Vicky hahneRobert uhlBrian sullivanCelcuity incCelcuity inc viewAnnual needham virtual healthcareChief executive officer

Celcuity Inc Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Dosing of first patient in VIKTORIA-1 in the fourth quarter triggered closing of $100 million PIPE financing and drawdown of $20 million term loan tranche, which extends cash runway through 2025Updated

United statesRobert uhlVicky hahneBrian sullivanDrug administrationCelcuity incAmerican association for cancer researchExchange commission onCelcuity inc viewBreakthrough therapySpotlight poster discussionAntonio breast cancer symposiumAmerican societyClinical oncology genitourinary cancersAmerican associationCancer research